Essayer OR - Gratuit
Heated startup race is on to capture AI-driven APAC healthcare
BioSpectrum Asia
|BioSpectrum Asia June 2021
The Artificial Intelligence (AI) ecosystem in healthcare has grown in the recent past, as companies are looking to capitalise on the benefits provided by AI to improve patient outcomes and enable convenient, cost-effective access to healthcare solutions. In addition to the significant increase in digital penetration and internet connectivity, favourable government policies (e.g., China, Thailand and the Philippines) have been key driving factors of growth in health-tech startups across the Asia Pacific (APAC) region. AI in the APAC healthcare market is set to grow substantially due to increasing investments by Venture Capitalists in AI healthcare startups, cross-industry partnerships and collaborations.
AI is being used by health-tech startups for various applications within the healthcare domain such as Patient Data Analytics, Medical Imaging, Lifestyle Monitoring, Drug Discovery, Vaccine Trials , Virtual Assistants, Wearables, Health-records, Mental Health & Wellness, and Robot-Assisted Surgery, Dosage Error Reduction among others. Medical Imaging based on Deep Learning Neural Networks (a sub-field of AI) can be used in diagnosing diseases with the help of historical data. AI can also be used in detecting cancerous tissues and diagnosing certain chronic heart diseases.
APAC lags in VC funding
In terms of total venture capital (VC) funding received by healthcare startups across the globe, North American startups accounted for approximately 60 per cent, followed by APAC startups with approximately 25 per cent; and European & Middle East and North Africa (MENA) startups with approximately 15 per cent of the total funding. In 2020, VC funding for APAC startups had increased by around 37 per cent Year over Year (YoY).
In 2020, within the healthcare domain for APAC-based startups, the Diagnostics sub-sector received around 20 per cent of the total funding; e-Marketplace received 15 per cent; followed by Insurance Tech and Nutrition & Wellness sub-sector with 10 per cent of the total VC funding.
Cette histoire est tirée de l'édition BioSpectrum Asia June 2021 de BioSpectrum Asia.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE BioSpectrum Asia
BioSpectrum Asia
India Health Fund supports D-Nome to bolster molecular TB screening in India
India Health Fund (IHF), a Tata Trusts initiative, is poised to transform tuberculosis (TB) screening at scale by enabling the development of the world's most affordable molecular screening tool for TB.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
BioOra and Octane Biotech sign LoI to expand cell therapy manufacturing using Cocoon Platform
BioOra, a commercialstage cell therapy company advancing CAR-T therapies for cancer patients, & Canadabased Octane Biotech Inc., an Octane Medical Group Company, has announced the signing of a Letter of Intent (LOI) to collaborate on the co-development & deployment of advanced cell therapies using the Cocoon automated cell therapy manufacturing platform.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
NTU and NHG Health partner to advance healthcare education in Singapore
NHG Health's inaugural E3 (Educate, Elevate, Evolve) conference, held recently, was marked by a new partnership with Nanyang Technological University (NTU) Singapore, signalling a significant step in advancing healthcare education through interdisciplinary collaboration.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
Gene Solutions introduces non-invasive prenatal screening technology triSure in Taiwan
Singapore-based startup Gene Solutions has introduced triSure, a revolutionary non-invasive prenatal screening technology.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
How FemTech Spurt in APAC is Redefining Healthcare
Despite representing half the global population, women's health has historically received only a fraction of healthcare innovation and investment.
4 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
China's Colossal Ageing Population and Low Birth Rate Challenge
China's recent policy initiatives pertaining to long-term care insurance, maternity insurance expansion, and primary healthcare reform reflect a coordinated attempt to address deep structural demographic challenges—most notably 'rapid population ageing' and declining birth rates.
2 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
"We need to prioritise research as several common AYA cancers are significantly under-studied in Asian populations"
At the SingHealth Presidents' Scientific and Partners in Social-care (SPSOC) Conference, Assistant Professor Eileen Poon, Senior Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS) delivered an enlightening presentation.
7 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
Shimadzu Scientific Instruments opens laboratory in San Francisco Bay Area
Shimadzu Scientific Instruments (SSI) has opened its new research and development (R&D) facility in South San Francisco, California, US.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
"Building a lean team with deep operational expertise increases likelihood of success in rare disease drug development"
More than 300 million people worldwide are impacted by over 10,000 rare diseases, i.e. more than cancer and AIDS combined.
5 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
Qiagen expands into bloodstream infection syndromic testing with new rapid QIAstat-Dx panel
Qiagen N.V. has announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.
1 min
BioSpectrum Asia May 2026
Translate
Change font size
